First-in-human study suggests intermittent PD-L1 blockade may influence biomarkers of neuronal and synaptic damage, but larger trials are needed to determine whether the approach can slow Alzheimer’s disease progression.

Researchers have reported encouraging early safety results from a first-in-human clinical trial evaluating an experimental antibody designed to reduce neuroinflammation in people with early Alzheimer’s disease.

The randomized, double-blind Phase 1b study evaluated IBC-Ab002, a short-lived antibody targeting programmed death-ligand 1 (PD-L1), an immune-regulatory protein involved in controlling inflammatory responses. The experimental therapy was developed to temporarily block PD-L1 while minimizing prolonged effects on the immune system.

Chronic inflammation is increasingly recognized as an important feature of Alzheimer’s disease and other age-related neurodegenerative disorders. Although the disease is closely associated with the accumulation of amyloid plaques, inflammation within brain tissue may contribute to continued neuronal damage and disease progression.

Preclinical studies in rodents had suggested that temporarily blocking PD-L1 could reduce neuroinflammation, protect nerve cells and slow aspects of neurodegeneration. Those findings provided the rationale for testing IBC-Ab002 in humans.

Forty participants received treatment

The Phase 1b trial enrolled 40 people with early Alzheimer’s disease across five ascending dose groups, ranging from 1 mg/kg to 30 mg/kg. Participants received four doses at three-month intervals and were monitored primarily for safety and tolerability.

The results were reassuring on those measures. Researchers reported no treatment-related serious adverse events and found no evidence of amyloid-related imaging abnormalities, an important potential complication associated with some Alzheimer’s therapies.

The study also included exploratory analyses of cerebrospinal fluid biomarkers associated with neuronal and synaptic damage. At week 48, the researchers observed directional changes favoring the 30 mg/kg dose.

However, none of the dose groups demonstrated statistically significant changes. The researchers attributed this in part to the study’s small sample size, emphasizing that the trial was designed primarily to evaluate safety rather than establish clinical efficacy.

A different approach to Alzheimer’s inflammation

IBC-Ab002 represents a different therapeutic strategy from treatments that directly target amyloid or tau proteins. Instead, it seeks to modify the immune environment surrounding the disease.

The approach is based on the idea that aging can disrupt the body’s ability to regulate inflammation and support the brain’s immune defenses. Multiple factors, including cellular aging, impaired waste clearance and changes in systemic immune function, may contribute to persistent inflammation in the aging brain.

Rather than attempting to eliminate all of these underlying causes, IBC-Ab002 is designed to intervene in one of the pathways that regulates the immune response.

The antibody was engineered with modifications intended to produce a short-lived treatment effect, including reduced interaction with the neonatal Fc receptor and silencing of Fc-mediated effector functions. The goal is to provide intermittent immune modulation rather than continuous blockade of PD-L1.

Larger trials will determine whether the approach works

While the Phase 1b findings provide preliminary evidence that IBC-Ab002 can be administered safely in people with early Alzheimer’s disease, they do not yet demonstrate that the treatment slows cognitive decline or disease progression.

The exploratory biomarker findings are potentially interesting, particularly at the highest dose tested, but the absence of statistically significant results means they should be interpreted cautiously.

The next stage of research will need to involve substantially larger and longer clinical trials capable of determining whether the biological signals observed in this small study translate into meaningful benefits for patients.

For now, the results provide an important early test of a novel strategy for addressing neuroinflammation in Alzheimer’s disease. If subsequent studies confirm both safety and efficacy, intermittent immune modulation could eventually become part of a broader approach to treating the complex inflammatory processes associated with neurodegeneration.